GSK to Acquire IDRx in Up-to $1.15 Billion Deal
January 15, 2025
GSK has entered into an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision therapeutics for GIST. The deal includes an upfront payment of $1 billion plus a potential additional $150 million success-based regulatory milestone payment.
- Buyers
- GSK
- Targets
- IDRx
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.